The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
 
Mohammed M. Milhem
Honoraria - Amgen; Blueprint Medicines; Immunocore; Trieza Therapeutics
Consulting or Advisory Role - Amgen; Blueprint Medicines; Immunocore; Trieza Therapeutics
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; OncoSec; Pierre Fabre
Research Funding - BMS Brazil (Inst); Merck (Inst)
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Research Funding - Merck Sharp & Dohme
 
Asim Amin
Consulting or Advisory Role - Merck
Speakers' Bureau - Bristol-Myers Squibb; Merck; Pfizer
Research Funding - Bristol-Myers Squibb; Merck
 
Christopher D. Lao
Research Funding - Bristol-Myers Squibb; Merck; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Robert Martin Conry
Speakers' Bureau - Amgen; Array BioPharma; Array BioPharma; Bristol-Myers Squibb; Merck; Novartis; Regeneron; Sanofi
 
Jason Hunt
No Relationships to Disclose
 
Gregory A. Daniels
Honoraria - Sanofi/Regeneron
Consulting or Advisory Role - Sanofi/Regeneron
Speakers' Bureau - Array BioPharma; Regeneron; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Nektar (Inst); Viralytics (Inst)
 
Mohammed Almubarak
No Relationships to Disclose
 
Montaser F. Shaheen
No Relationships to Disclose
 
Theresa Michelle Medina
No Relationships to Disclose
 
Minal A. Barve
No Relationships to Disclose
 
Sarwan K. Bishnoi
No Relationships to Disclose
 
Ehtesham A. Abdi
No Relationships to Disclose
 
Michael Jon Chisamore
Employment - Merck
 
Biao Xing
Employment - Dynavax Technologies
 
Albert Candia
Employment - Dynavax Technologies
Stock and Other Ownership Interests - Dynavax Technologies
 
Erick Gamelin
Employment - Dynavax Technologies
Stock and Other Ownership Interests - Dynavax Technologies
 
Robert Janssen
Employment - Dynavax Technologies
Leadership - Dynavax Technologies
Stock and Other Ownership Interests - Dynavax Technologies; Merck
 
Antoni Ribas
Stock and Other Ownership Interests - Advaxis; Arcus Biosciences; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; ImaginAb; Lutris; Merus; PACT Pharma; Rgenix; Tango Therapeutics
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis